Brucellosis

Disease Analysis

Description and characteristics.

Pathogen

Comments NA

Variability of the disease

Comments NA

Stability of the agent/pathogen in the environment

Comments NA

Species involved

Animal infected/carrier/disease

Comments NA

Human infected/disease

Comments NA

Vector cyclical/non-cyclical

Comments NA

Reservoir

Comments NA

Description of infection & disease in natural hosts

Transmissibility

Comments NA

Pathogenic life cycle stages

Comments NA

Signs / Morbidity

Comments NA

Incubation period

Comments NA

Mortality

Comments NA

Shedding kinetic patterns

Comments NA

Mechanism of pathogenicity

Comments NA

Zoonotic potential

Reported incidence in humans

Comments NA

Risk of occurence in humans, populations at risk, specific risk factors

Comments NA

Symptoms described in humans

Comments NA

Level of under-reporting in humans

Comments NA

Likelihood of spread in humans

Comments NA

Impact on animal welfare and biodiversity

Both disease and prevention/control measures related

Comments NA

Endangered wild species affected or not

Comments NA

Slaughter necessity

Comments NA

Geographical distribution and spread

Current occurence/distribution

Comments NA

Epizootic/endemic- if epidemic frequency of outbreaks

Comments NA

Seasonal cycle

Comments NA

Speed of spatial spread during an outbreak

Comments NA

Transboundary potential of the disease

Comments NA

Seasonal cycle linked to climate

Comments NA

Distribution of disease or vector linked to climate

Comments NA

Outbreaks linked to extreme weather

Comments NA

Sensitivity of disease or vectors to the effects of climate change

Comments NA

Route of Transmission

Usual mode of transmission

Comments NA

Occasional mode of transmission

Comments NA

Conditions that favour spread

Comments NA

Detection and Immune response to infection

Mechanism of host response

Comments NA

Immunological basis of diagnosis

Comments NA

Main means of prevention, detection and control

Sanitary measures

Comments NA

Mechanical and biological control

Comments NA

Diagnostic tools

Comments NA

Vaccines

Comments NA

Therapeutics

Comments NA

Biosecurity measures

Comments NA

Border/trade/movement control

Comments NA

Prevention tools

Comments NA

Surveillance

Comments NA

Experiences/success (and failures) of prevention, control, eradication in other countries

Comments NA

Costs of above measures

Comments NA

Disease outbreaks reported to OIE in last 18 months

Number of reports

Comments NA

Date

Comments NA

Delay between first suspicion / first confirmation and OIE first emergency notification

Comments NA

Frequency of follow-up reports

Comments NA

Level of under-reporting

Comments NA

Socio-economic impact

Human

Comments NA

Impact on affected individuals and/or aggregated DALY figures

Comments NA

Cost of treatment and control of the disease in humans

Comments NA

Animal

Comments NA

Direct impact (a) on production

Comments NA

Direct impact (b) cost of private and public control measures

Comments NA

Indirect impact

Comments NA

Trade implications

Impact on international trade/exports from the EU

Comments NA

Impact on EU intra-community trade

Comments NA

Impact on national trade

Comments NA

Main perceived obstacles for effective prevention and control

Comments NA

Main perceived facilitators for effective prevention and control

Comments NA

Diagnostics availability

Commercial diagnostic kits available worldwide

Comments NA

Commercial diagnostic kits available in Europe

Comments NA

Diagnostic kits validated by National or International Standards

Comments NA

Diagnostic method(s) described by International Standards (e.g. OIE, EU)

Comments NA

Commercial potential for diagnostic kits in Europe

Comments NA

DIVA tests required and/or available

Comments NA

Opportunities for new developments

Comments NA

Vaccines availability

Commercial vaccines availability (globally)

Comments NA

Commercial vaccines authorised in Europe

Comments NA

Marker vaccines available worldwide

Comments NA

Marker vaccines authorised in Europe

Comments NA

Effectiveness of vaccines / Main shortcomings of current vaccines

Comments NA

Commercial potential for vaccines in Europe

Regulatory and/or policy challenges to approval

Comments NA

Commercial feasibility (e.g manufacturing)

Comments NA

Opportunity for barrier protection

Comments NA

Opportunity for new developments

Comments NA

Pharmaceutical availability

Current therapy (curative and preventive)

Comments NA

Future therapy

Commercial potential for pharmaceuticals in Europe

Comments NA

Regulatory and/or policy challenges to approval

Comments NA

Commercial feasibility (e.g manufacturing)

Comments NA

Opportunities for new developments

Comments NA

New developments for diagnostic tests

Requirements for diagnostics development

Comments NA

Time to develop new or improved diagnostics and their validation

Comments NA

Cost of developing new or improved diagnostics and their validation

Comments NA

Research requirements for new or improved diagnostics

Comments NA

Technologies to determine virus freedom in animals

Comments NA

New developments for vaccines

Requirements for vaccines development / main characteristics for improved vaccines

Comments NA

Time to develop new or improved vaccines

Comments NA

Cost of developing new or improved vaccines and their validation

Comments NA

Research requirements for new or improved vaccines

Comments NA

New developments for pharmaceuticals

Requirements for pharmaceuticals development

Comments NA

Time to develop new or improved pharmaceuticals

Comments NA

Cost of developing new or improved pharmaceuticals and their validation

Comments NA

Research requirements for new or improved pharmaceuticals

Comments NA

Risks

Conclusion